Journal articles on the topic 'Tyrosine Kinase Inhibitors Targeting'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Tyrosine Kinase Inhibitors Targeting.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
Deininger, Michael. "Targeting Tyrosine Kinase Receptors." Blood 122, no. 21 (November 15, 2013): SCI—25—SCI—25. http://dx.doi.org/10.1182/blood.v122.21.sci-25.sci-25.
Full textChen, Jin-Shuen, Li-Chien Chang, Shyh-Jer Huang, and Chao-Wen Cheng. "Targeting Spleen Tyrosine Kinase-Bruton’s Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis." BioMed Research International 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/814869.
Full textForster, Michael, Xiaojun Julia Liang, Martin Schröder, Stefan Gerstenecker, Apirat Chaikuad, Stefan Knapp, Stefan Laufer, and Matthias Gehringer. "Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK." International Journal of Molecular Sciences 21, no. 23 (December 4, 2020): 9269. http://dx.doi.org/10.3390/ijms21239269.
Full textManzo, Lawaly Maman, Moudirat Lawaly, and Lui YU. "Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small cell lung cancer." Indian Journal of Pharmaceutical and Biological Research 3, no. 02 (June 30, 2015): 81–87. http://dx.doi.org/10.30750/ijpbr.3.2.10.
Full textCher, Chae Yin, Cheuk Him Man, Stephen S. Y. Lam, Eric S. K. Ho, Nelson K. L. Ng, Marie-Anne Hospital, Jerome Tamburini, and Anskar Y. H. Leung. "Targeting Polo-like Kinase in Acute Myeloid Leukemia." Blood 124, no. 21 (December 6, 2014): 2234. http://dx.doi.org/10.1182/blood.v124.21.2234.2234.
Full textGrimminger, Friedrich, Ralph T. Schermuly, and Hossein A. Ghofrani. "Targeting non-malignant disorders with tyrosine kinase inhibitors." Nature Reviews Drug Discovery 9, no. 12 (December 2010): 956–70. http://dx.doi.org/10.1038/nrd3297.
Full textPasquet, Jean-Max, Romain Gioia, Claire Drullion, Valerie Lagarde, Cedric Leroy, Serge Roche, Bruno Cardinaud, and Francois-Xavier Mahon. "Tyrosine Kinase Proteins profiling of Nilotinib Resistant Chronic Myelogenous Leukemia Cells Unravels a Tyrosine Kinase-Mediated Bypass." Blood 114, no. 22 (November 20, 2009): 2175. http://dx.doi.org/10.1182/blood.v114.22.2175.2175.
Full textSakle, Nikhil S., Shweta A. More, Sachin A. Dhawale, and Santosh N. Mokale. "Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery." Current Drug Discovery Technologies 17, no. 5 (December 23, 2020): 585–615. http://dx.doi.org/10.2174/1570163816666190808120843.
Full textvan der Kuip, Heiko, Lara Wohlbold, Carsten Oetzel, Matthias Schwab, and Walter E. Aulitzky. "Mechanisms of Clinical Resistance to Small Molecule Tyrosine Kinase Inhibitors Targeting Oncogenic Tyrosine Kinases." American Journal of PharmacoGenomics 5, no. 2 (2005): 101–12. http://dx.doi.org/10.2165/00129785-200505020-00003.
Full textShojaee, Seyedmehdi, Maike Buchner, Huimin Geng, Bolland Silvia, Phillip Koeffler, and Markus Muschen. "Targeting Inhibitory Phosphatases in Tyrosine Kinase-Driven Leukemias." Blood 118, no. 21 (November 18, 2011): 1382. http://dx.doi.org/10.1182/blood.v118.21.1382.1382.
Full textDassonville, Olivier, Alexandre Bozec, Jean Louis Fischel, and Gerard Milano. "EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors." Critical Reviews in Oncology/Hematology 62, no. 1 (April 2007): 53–61. http://dx.doi.org/10.1016/j.critrevonc.2006.12.008.
Full textLipsky, Andrew, and Nicole Lamanna. "Managing toxicities of Bruton tyrosine kinase inhibitors." Hematology 2020, no. 1 (December 4, 2020): 336–45. http://dx.doi.org/10.1182/hematology.2020000118.
Full textKutsch, Nadine, Reinhard Marks, Richard Ratei, Thomas K. Held, and Martin Schmidt-Hieber. "Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell Neoplasms." Biomarker Insights 10s3 (January 2015): BMI.S22434. http://dx.doi.org/10.4137/bmi.s22434.
Full textYamaoka, Toshimitsu, Sojiro Kusumoto, Koichi Ando, Motoi Ohba, and Tohru Ohmori. "Receptor Tyrosine Kinase-Targeted Cancer Therapy." International Journal of Molecular Sciences 19, no. 11 (November 6, 2018): 3491. http://dx.doi.org/10.3390/ijms19113491.
Full textLogie, Emilie, Chandra S. Chirumamilla, Claudina Perez-Novo, Priyanka Shaw, Ken Declerck, Ajay Palagani, Savithri Rangarajan, et al. "Covalent Cysteine Targeting of Bruton’s Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells." Cancers 13, no. 7 (March 31, 2021): 1618. http://dx.doi.org/10.3390/cancers13071618.
Full textGarcía-Aranda, Marilina, and Maximino Redondo. "Targeting Receptor Kinases in Colorectal Cancer." Cancers 11, no. 4 (March 27, 2019): 433. http://dx.doi.org/10.3390/cancers11040433.
Full textK. Bhanumathy, Kalpana, Amrutha Balagopal, Frederick S. Vizeacoumar, Franco J. Vizeacoumar, Andrew Freywald, and Vincenzo Giambra. "Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia." Cancers 13, no. 2 (January 7, 2021): 184. http://dx.doi.org/10.3390/cancers13020184.
Full textK. Bhanumathy, Kalpana, Amrutha Balagopal, Frederick S. Vizeacoumar, Franco J. Vizeacoumar, Andrew Freywald, and Vincenzo Giambra. "Protein Tyrosine Kinases: Their Roles and Their Targeting in Leukemia." Cancers 13, no. 2 (January 7, 2021): 184. http://dx.doi.org/10.3390/cancers13020184.
Full textStaudt, Dilana, Heather Murray, Tabitha McLachlan, Frank Alvaro, Anoop Enjeti, Nicole Verrills, and Matthew Dun. "Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance." International Journal of Molecular Sciences 19, no. 10 (October 16, 2018): 3198. http://dx.doi.org/10.3390/ijms19103198.
Full textLevis, Mark, and Alexander E. Perl. "Gilteritinib: potent targeting of FLT3 mutations in AML." Blood Advances 4, no. 6 (March 24, 2020): 1178–91. http://dx.doi.org/10.1182/bloodadvances.2019000174.
Full textBaselga, José, and Carlos L. Arteaga. "Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer." Journal of Clinical Oncology 23, no. 11 (April 10, 2005): 2445–59. http://dx.doi.org/10.1200/jco.2005.11.890.
Full textRendell, Aimee, Isobel Thomas-Bland, Lee McCuish, Christopher Taylor, Mudra Binju, and Yu Yu. "Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?" Biomedicines 10, no. 9 (August 29, 2022): 2113. http://dx.doi.org/10.3390/biomedicines10092113.
Full textPaatero, Ilkka, Ville Veikkolainen, Matias Mäenpää, Etienne Schmelzer, Heinz-Georg Belting, Lauri J. Pelliniemi, and Klaus Elenius. "ErbB4 tyrosine kinase inhibition impairs neuromuscular development in zebrafish embryos." Molecular Biology of the Cell 30, no. 2 (January 15, 2019): 209–18. http://dx.doi.org/10.1091/mbc.e18-07-0460.
Full textMelgar, Katelyn, Morgan M. Walker, LaQuita M. Jones, Lyndsey C. Bolanos, Kathleen Hueneman, Mark Wunderlich, Jian-Kang Jiang, et al. "Overcoming adaptive therapy resistance in AML by targeting immune response pathways." Science Translational Medicine 11, no. 508 (September 4, 2019): eaaw8828. http://dx.doi.org/10.1126/scitranslmed.aaw8828.
Full textOta, Yoko, Hiroyuki Yoda, Takahiro Inoue, Takayoshi Watanabe, Yoshinao Shinozaki, Atsushi Takatori, and Hiroki Nagase. "Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides." PLOS ONE 16, no. 9 (September 30, 2021): e0257718. http://dx.doi.org/10.1371/journal.pone.0257718.
Full textMoradpour, Zahra, and Leila Barghi. "Novel Approaches for Efficient Delivery of Tyrosine Kinase Inhibitors." Journal of Pharmacy & Pharmaceutical Sciences 22 (January 13, 2019): 37–48. http://dx.doi.org/10.18433/jpps29891.
Full textSos, Martin L., Hannah Lea Tumbrink, Carsten Schultz-Fademrecht, Jonas Lategahn, Marina Keul, Janina Niggenaber, Alena Heimsoeth, et al. "Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001." Journal of Clinical Oncology 37, no. 15_suppl (May 20, 2019): e14718-e14718. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.e14718.
Full textChase, Andrew, and Nicholas C. P. Cross. "Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases." Clinical Science 111, no. 4 (September 13, 2006): 233–49. http://dx.doi.org/10.1042/cs20060035.
Full textChew, Serena, Melissa C. Mackey, and Elias Jabbour. "Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation." Therapeutic Advances in Hematology 11 (January 2020): 204062072093061. http://dx.doi.org/10.1177/2040620720930614.
Full textAmelia, Tasia, Rahmana Emran Kartasasmita, Tomohiko Ohwada, and Daryono Hadi Tjahjono. "Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors." Molecules 27, no. 3 (January 26, 2022): 819. http://dx.doi.org/10.3390/molecules27030819.
Full textAubry, Arthur, Stéphane Galiacy, and Michèle Allouche. "Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides." Cancers 11, no. 3 (February 26, 2019): 275. http://dx.doi.org/10.3390/cancers11030275.
Full textHsu, Jonathan, Jun Zhang, Chris Kitson, Seng-Lai Tan, Satwant Narula, Julie A. DeMartino, and Cheng Liao. "Development of a Pharmacodynamic Assay Based on PLCγ2 Phosphorylation for Quantifying Spleen Tyrosine Kinase (SYK)–Bruton’s Tyrosine Kinase (BTK) Signaling." Journal of Biomolecular Screening 18, no. 8 (May 23, 2013): 890–98. http://dx.doi.org/10.1177/1087057113489881.
Full textAlcalá, Sonia, Víctor Mayoral-Varo, Laura Ruiz-Cañas, Juan Carlos López-Gil, Christopher Heeschen, Jorge Martín-Pérez, and Bruno Sainz. "Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells." International Journal of Molecular Sciences 21, no. 20 (October 9, 2020): 7437. http://dx.doi.org/10.3390/ijms21207437.
Full textNelson, Erik A., Sarah R. Walker, Ellen Weisberg, Michal Bar-Natan, Rosemary Barrett, Laurie B. Gashin, Shariya Terrell, et al. "The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors." Blood 117, no. 12 (March 24, 2011): 3421–29. http://dx.doi.org/10.1182/blood-2009-11-255232.
Full textChen, Yun, Yao Guo, Wanting Ho, and Zhizhuang Joe. "Identification and Characterization Of a Potent FLT3 Inhibitor." Blood 122, no. 21 (November 15, 2013): 5027. http://dx.doi.org/10.1182/blood.v122.21.5027.5027.
Full textCapparelli, Claudia, Timothy Purwin, and Andrew Aplin. "Abstract B05: Sox10 differentially regulates receptor tyrosine kinase expression in melanomas." Cancer Research 80, no. 19_Supplement (October 1, 2020): B05. http://dx.doi.org/10.1158/1538-7445.mel2019-b05.
Full textThomas, Christan M., and Peter Campbell. "FLT3 inhibitors in acute myeloid leukemia: Current and future." Journal of Oncology Pharmacy Practice 25, no. 1 (September 30, 2018): 163–71. http://dx.doi.org/10.1177/1078155218802620.
Full textCho, Hyewon, Eun Lee, Hye Ah Kwon, Lee Seul, Hui-Jeon Jeon, Ji Hoon Yu, Jae-Ha Ryu, and Raok Jeon. "Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity." International Journal of Molecular Sciences 21, no. 21 (October 25, 2020): 7919. http://dx.doi.org/10.3390/ijms21217919.
Full textTyner, Jeffrey W., Stephanie Willis, Michael W. N. Deininger, and Brian J. Druker. "RNAi Functional Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Acute Myeloid Leukemia Patients." Blood 110, no. 11 (November 16, 2007): 208. http://dx.doi.org/10.1182/blood.v110.11.208.208.
Full textOlsen, Colin E., Eric S. Gourley, Xiao-Hui Lui, Jeff Walker, Cory L. Grand, Steven L. Warner, Hariprasad Vankayalapati, and David J. Bearss. "Targeting the JAK2 Kinase in Hematological Malignancies." Blood 110, no. 11 (November 16, 2007): 3560. http://dx.doi.org/10.1182/blood.v110.11.3560.3560.
Full textPadi, Sathish Kumar Reddy, Libia A. Luevano, Ningfei An, Ritu Pandey, Neha Singh, Jin H. Song, Jon C. Aster, Xue-Zhong Yu, Shikhar Mehrotra, and Andrew S. Kraft. "Therapeutic Targeting of PIM Protein Kinases in a Subset of T-Cell Acute Lymphoblastic Leukemia." Blood 128, no. 22 (December 2, 2016): 2742. http://dx.doi.org/10.1182/blood.v128.22.2742.2742.
Full textManouchehri, Ali, Elishama Kanu, Michael J. Mauro, Aaron W. Aday, Jonathan R. Lindner, and Javid Moslehi. "Tyrosine Kinase Inhibitors in Leukemia and Cardiovascular Events." Arteriosclerosis, Thrombosis, and Vascular Biology 40, no. 2 (February 2020): 301–8. http://dx.doi.org/10.1161/atvbaha.119.313353.
Full textZheng, Tony J., Elizabeth R. Lofurno, Alexander R. Melrose, Hari Hara Sudhan Lakshmanan, Jiaqing Pang, Kevin G. Phillips, Meghan E. Fallon, et al. "Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function." American Journal of Physiology-Cell Physiology 320, no. 5 (May 1, 2021): C902—C915. http://dx.doi.org/10.1152/ajpcell.00296.2020.
Full textNordigården, Amanda, Maria Kraft, Pernilla Eliasson, Verena Labi, Eric W. F. Lam, Andreas Villunger, and Jan-Ingvar Jönsson. "BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor–induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3." Blood 113, no. 10 (March 5, 2009): 2302–11. http://dx.doi.org/10.1182/blood-2008-07-167023.
Full textLeung, John SM. "Cost-effectiveness of epidermal growth factor receptor-targeting tyrosine kinase inhibitors." Hong Kong Medical Journal 20, no. 5 (October 8, 2014): 465. http://dx.doi.org/10.12809/hkmj144336.
Full textYu, Xiangfan, Simei Qiu, Dongshan Sun, Pei Guo, and Quhuan Li. "Comparison of Intermolecular Interactions of Irreversible and Reversible Inhibitors with Bruton’s Tyrosine Kinase via Molecular Dynamics Simulations." Molecules 27, no. 21 (November 2, 2022): 7451. http://dx.doi.org/10.3390/molecules27217451.
Full textWeatherald, Jason, Louise Bondeelle, Marie-Camille Chaumais, Christophe Guignabert, Laurent Savale, Xavier Jaïs, Olivier Sitbon, et al. "Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors." European Respiratory Journal 56, no. 4 (June 11, 2020): 2000279. http://dx.doi.org/10.1183/13993003.00279-2020.
Full textWei, Jia, Ling Ma, Chenglong Li, Christopher R. Pierson, Jonathan L. Finlay, and Jiayuh Lin. "Targeting Upstream Kinases of STAT3 in Human Medulloblastoma Cells." Current Cancer Drug Targets 19, no. 7 (August 2, 2019): 571–82. http://dx.doi.org/10.2174/1568009618666181016165604.
Full textLv, Jiahui, Jingde Wu, Feng He, Ying Qu, Qiuqiong Zhang, and Chenggong Yu. "Development of Bruton’s Tyrosine Kinase Inhibitors for Rheumatoid Arthritis." Current Medicinal Chemistry 25, no. 42 (February 6, 2019): 5847–59. http://dx.doi.org/10.2174/0929867325666180316121951.
Full textHu, Chunqi, and Xiaowu Dong. "Cysteine-targeted Irreversible Inhibitors of Tyrosine Kinases and Key Interactions." Current Medicinal Chemistry 26, no. 31 (November 19, 2019): 5811–24. http://dx.doi.org/10.2174/0929867325666180713124223.
Full text